港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,793.042

+20.8101.17%

漲家數：4

跌家數：4

平家數：- -

市盈率：- -

高：1,835.570

開：1,770.415

低：1,747.549

收：1,772.232

資料載入中...

聯邦制藥(03933.HK)UBT251注射液獲美FDA批准新藥臨牀試驗

阿斯达克财经

聯邦制藥(03933)研發的UBT251 注射液 CKD 適應症獲美國 FDA 批准新藥臨牀試驗

康泰生物(300601.SZ)子公司收到吸附破傷風疫苗Ⅰ/Ⅲ期臨牀試驗總結報告

華東醫藥(000963.SZ)：多肽類人GLP-1受體和GIP受體的雙靶點長效激動劑HDM1005注射液臨牀試驗獲批

藥明康德將於3月17日審議年度業績及股息策略

康龍化成收盤上漲1.51%，滾動市盈率25.33倍，總市值477.27億元

康龍化成3月3日現1筆大宗交易成交金額1333.5萬元

新浪证券-红岸工作室

昭衍新藥(06127)截至2月末累計回購A股股份326.98萬股

智通财经网

【黑石擬收購日本臨牀研究機構CMIC六成權益或涉及數億美元】全球最大另類資產管理人黑石正收購一家專注於幫助製藥公司在日本進行臨牀試驗的公司CMIC Co.，反映其對日本老齡化人口健康需求的興趣日益增加。據悉，黑石同意收購CMIC Co. 60%股權，惟未有透露具體金額，僅指交易的價值可達數億美元。黑石日本私募股權主管Atsuhiko Sakamoto曾在訪問中表示，日本的臨牀試驗過程效率頗低，對比其他市場需時非常長。它們目前將簡化過程，可以更快介紹新藥到日本，而黑石可以從中作出貢獻。

港股異動 | 來凱醫藥-B(02105)漲超8% 自研新藥LAE120獲美國FDA臨牀試驗批准

方達控股盤中異動股價大跌7.32%

藥明康德盤中異動股價大漲3.03%

昭衍新藥盤中異動股價大漲5.75%報13.980港元

藥明生物(02269)出現大手賣出31.45萬股，成交價$22.45，涉資706.052萬

阿斯达克财经

【百利天恆：BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌 III 期臨牀試驗完成首例受試者入組】金融界3月2日消息，百利天恆自主研發的創新生物藥注射用 BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌的 III 期臨牀試驗已於近日完成首例受試者入組。BL-B01D1 是全球獨家處於 III 期註冊臨牀試驗階段的可同時靶向 EGFR 和 HER3 的雙抗 ADC 藥物。截至目前，BL-B01D1 正在中國和美國進行約 30 項針對多種腫瘤類型的臨牀試驗，除本次新入組的臨牀試驗外，其在肺癌、乳腺癌、鼻咽癌、食管鱗癌等 7 項國內 III 期註冊臨牀試驗也處於受試者入組階段。藥品需完成臨牀試驗並通過審評審批方可上市銷售，且醫藥產品具有高科技、高風險等特點，容易受到不確定性因素影響。

康希諾業績出爐，營收大增137%，股價不漲反跌？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1793.0419,"timestamp":1741334919514,"preClose":1772.232,"halted":0,"volume":105965997,"delay":0,"changeRate":0.011742,"change":20.809814,"pbRate":2.65369,"amount":2334342230,"amplitude":0.049667,"prevYearClose":1395.7731,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"turnoverRate":0.008873,"marketCap":381645564416,"floatMarketCap":165840598400,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1835.5696,"amplitude":0.049667,"preClose":1772.232,"low":1747.5487,"pbRate":"2.65369","latestPrice":1793.0419,"volume":105965997,"delay":0,"open":1770.415,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"sixtyDayClose":1337.64,"secType":"PLATE","market":"HK","turnoverRate":0.008873,"peRate":33.079805,"marketCap":381645564416,"floatMarketCap":165840598400,"timestamp":1741334919514,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":4,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516250655","title":"聯邦制藥(03933.HK)UBT251注射液獲美FDA批准新藥臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516250655","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516250655?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 00:35","pubTimestamp":1741019700,"startTime":"0","endTime":"0","summary":"联邦制药(03933.HK) 公布，全资附属联邦生物科技(珠海横琴)自主研发的1类创新药UBT251注射液获美国药品监督管理局“FDA”许可，同意开展慢性肾脏病“CKD”适应症II期临床试验。此前，CKD适应症已获得中国国家药品监督管理局临床试验批准。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421743/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03933","BK1576","BK1141","BK1191","BK1583","03347"],"gpt_icon":0},{"id":"2516631305","title":"聯邦制藥(03933)研發的UBT251 注射液 CKD 適應症獲美國 FDA 批准新藥臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631305","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631305?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 22:18","pubTimestamp":1741011490,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 公布，近日，公司全资附属公司联邦生物科技有限公司自主研发的 1 类创新药 UBT251 注射液获得美国药品监督管理局许可，同意开展慢性肾脏病适应症 II 期临床试验。此前，CKD 适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。目前，成人 2 型糖尿病、超重或肥胖、CKD 等多个适应症已取得中国及美国两地药物临床试验批准，并已于中国率先进入临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","BK1576","BK1141","03347","03933"],"gpt_icon":0},{"id":"2516898026","title":"康泰生物(300601.SZ)子公司收到吸附破傷風疫苗Ⅰ/Ⅲ期臨牀試驗總結報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2516898026","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516898026?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 18:28","pubTimestamp":1740997699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司全资子公司北京民海生物科技有限公司(“民海生物”)近日收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告，民海生物研发的吸附破伤风疫苗临床研究阶段工作顺利完成。研究结果显示，民海生物研制的吸附破伤风疫苗应用于成人免疫具有良好的安全性和免疫原性。本次吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告的取得表明吸附破伤风疫苗具备了申报生产的必备条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","BK0201","BK0239","BK0046","300601","03347","159646"],"gpt_icon":0},{"id":"2516856686","title":"華東醫藥(000963.SZ)：多肽類人GLP-1受體和GIP受體的雙靶點長效激動劑HDM1005注射液臨牀試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2516856686","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516856686?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:47","pubTimestamp":1740995243,"startTime":"0","endTime":"0","summary":"据悉，HDM1005注射液是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类化学新药，是多肽类人GLP-1受体和GIP受体的双靶点长效激动剂。HDM1005注射液为多肽类人GLP-1受体和GIP受体的双靶点长效激动剂，GLP-1类产品具有减肥、降糖和心血管获益等作用，是相对成熟和安全的靶点。本次HDM1005注射液临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在内分泌治疗领域的核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK4590","BK1576","000963","BK1141","LU1969619763.USD","03347","BK0209","LU2328871848.SGD","BK4144","GLP","BK0187","BK1583","BK0188","BK0175","BK0183","BK0196"],"gpt_icon":0},{"id":"2516685550","title":"藥明康德將於3月17日審議年度業績及股息策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2516685550","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516685550?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:44","pubTimestamp":1740995064,"startTime":"0","endTime":"0","summary":"3月3日，药明康德（603259/02359）发布公告，将于2025年3月17日召开董事会会议，主要内容包括考虑和批准截至2024年12月31日的年度业绩及建议的末期股息（如有）。公告并未透露具体的财务数据或业绩变化，因此无法提供相关的数字信息。此次董事会会议的召开旨在审议公司整体的经营情况及未来的股东回报策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503033334901567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2045819591.USD","BK1576","LU1046422090.SGD","BK1141","LU2242644610.SGD","LU0052750758.USD","02359","BK1583","LU0708995583.HKD","LU2125910500.SGD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2516836896","title":"康龍化成收盤上漲1.51%，滾動市盈率25.33倍，總市值477.27億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516836896","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516836896?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:27","pubTimestamp":1740994020,"startTime":"0","endTime":"0","summary":"3月3日，康龙化成今日收盘26.84元，上涨1.51%，滚动市盈率PE达到25.33倍，总市值477.27亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均47.53倍，行业中值43.87倍，康龙化成排名第18位。消息面上，康龙化成10月30日接待中金证券等38家机构调研，上市公司接待人员包括首席财务官、董事会秘书李承宗。最新一期业绩显示，2024年三季报，公司实现营业收入88.17亿元，同比3.00%；净利润14.22亿元，同比24.82%，销售毛利率33.87%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/03172748487215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","300759","BK1141","BK1576","03759"],"gpt_icon":0},{"id":"2516688502","title":"康龍化成3月3日現1筆大宗交易 成交金額1333.5萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688502","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516688502?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:00","pubTimestamp":1740992400,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　3月3日，康龙化成收涨1.51%，收盘价为26.84元，发生1笔大宗交易，合计成交量50万股，成交金额1333.5万元。　　第1笔成交价格为26.67元，成交50.00万股，成交金额1,333.50万元，溢价率为-0.63%，买方营业部为机构专用，卖方营业部为中信证券华南股份有限公司广州万博证券营业部。　　进一步统计，近3个月内该股累计发生15笔大宗交易，合计成交金额为2.21亿元。该股近5个交易日累计下跌5.53%，主力资金合计净流出1.3亿元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-03-03/doc-inenkmnh6633129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","300759","BK1141","BK1576","03759"],"gpt_icon":0},{"id":"2516683654","title":"昭衍新藥(06127)截至2月末累計回購A股股份326.98萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683654","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683654?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 16:57","pubTimestamp":1740992257,"startTime":"0","endTime":"0","summary":"昭衍新药(06127)发布公告，2025年2月，公司未回购A股股份。截至2025年...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0216","159982","603127","06127","BK1141","399300","BK1576"],"gpt_icon":0},{"id":"2516157074","title":"【黑石擬收購日本臨牀研究機構CMIC六成權益 或涉及數億美元】全球最大另類資產管理人黑石正收購一家專注於幫助製藥公司在日本進行臨牀試驗的公司CMIC Co.，反映其對日本老齡化人口健康需求的興趣日益增加。據悉，黑石同意收購CMIC Co. 60%股權，惟未有透露具體金額，僅指交易的價值可達數億美元。黑石日本私募股權主管Atsuhiko Sakamoto曾在訪問中表示，日本的臨牀試驗過程效率頗低，對比其他市場需時非常長。它們目前將簡化過程，可以更快介紹新藥到日本，而黑石可以從中作出貢獻。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516157074","media":"金融界","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516157074?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 14:39","pubTimestamp":1740983998,"startTime":"0","endTime":"0","summary":"全球最大另类资产管理人黑石正收购一家专注于帮助制药公司在日本进行临床试验的公司CMIC Co.，反映其对日本老龄化人口健康需求的兴趣日益增加。据悉，黑石同意收购CMIC Co. 60%股权，惟未有透露具体金额，仅指交易的价值可达数亿美元。黑石日本私募股权主管Atsuhiko Sakamoto曾在访问中表示，日本的临床试验过程效率颇低，对比其他市场需时非常长。它们目前将简化过程，可以更快介绍新药到日本，而黑石可以从中作出贡献。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03143948480931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","03347","BX","IE0004445239.USD","BK1542","BK1258","BK4585","BK4135","BK1574","BK1141","BK1583","09983","IE00BBT3K403.USD","IE00BGHQF748.EUR","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","IE00B64PRP62.GBP","BK1576","IE00B3QW5Z07.USD","BK4588","BK1229","01477","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2516575333","title":"港股異動 | 來凱醫藥-B(02105)漲超8% 自研新藥LAE120獲美國FDA臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516575333","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516575333?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 11:29","pubTimestamp":1740972568,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B涨超8%，截至发稿，涨8.63%，报13.6港元，成交额8370.23万港元。消息面上，来凯医药今早宣布，美国食品药品监督管理局已批准其自主研发的LAE120，一种强效、高选择性USP1抑制剂的新药临床试验申请，用于治疗晚期实体瘤患者。公司表示正积极开展外部合作以加快LAE120临床开发进展。除LAE120，来凯自主研发的另一款抗肿瘤潜在药物LAE118也进入了IND支持性研究阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1576","BK1161","BK1141","BK1583","03347"],"gpt_icon":0},{"id":"2516827578","title":"方達控股盤中異動 股價大跌7.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516827578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516827578?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 10:43","pubTimestamp":1740969816,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘10时43分，方达控股股票出现波动，股价急速下跌7.32%。截至发稿，该股报1.140港元/股，成交量62.6万股，换手率0.03%，振幅8.13%。资金方面，该股资金流入12.184万港元，流出58.574万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予卖出建议，无券商给予买入、持有建议。方达控股股票所在的生物技术行业中，整体涨幅为0.14%。北美和欧洲部门包括美国、加拿大和欧洲。中国部门包括中国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303104336989943e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303104336989943e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1583","01521","BK1576"],"gpt_icon":0},{"id":"2516752201","title":"藥明康德盤中異動 股價大漲3.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752201?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 09:52","pubTimestamp":1740966740,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时52分，药明康德股票出现异动，股价快速拉升3.03%。截至发稿，该股报61.150港元/股，成交量103.643万股，换手率0.27%，振幅2.95%。资金方面，该股资金流入3389.47万港元，流出1549.52万港元。药明康德股票所在的生物技术行业中，整体跌幅为1.33%。其相关个股中，昭衍新药、科济药业-B、云顶新耀-B涨幅较大，振幅较大的相关个股有创胜集团-B、永泰生物-B、百奥赛图-B，振幅分别为20.41%、11.31%、10.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030309522098993174&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030309522098993174&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0708995583.HKD","LU2125910500.SGD","LU2045819591.USD","LU0052750758.USD","LU0320764599.SGD","02359","LU2242644610.SGD","BK1583","BK1576","LU1046422090.SGD","BK1141"],"gpt_icon":0},{"id":"2516524796","title":"昭衍新藥盤中異動 股價大漲5.75%報13.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516524796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516524796?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 09:44","pubTimestamp":1740966258,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时44分，昭衍新药股票出现波动，股价急速上涨5.75%。截至发稿，该股报13.980港元/股，成交量60.84万股，换手率0.51%，振幅4.99%。资金方面，该股资金流入457.631万港元，流出235.721万港元。昭衍新药股票所在的生物技术行业中，整体涨幅为0.23%。其相关个股中，昭衍新药、科济药业-B、圣诺医药-B涨幅较大，振幅较大的相关个股有创胜集团-B、永泰生物-B、腾盛博药-B，振幅分别为20.41%、11.31%、8.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303094418abe537b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303094418abe537b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1141","BK1576"],"gpt_icon":0},{"id":"2516727521","title":"藥明生物(02269)出現大手賣出31.45萬股，成交價$22.45，涉資706.052萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2516727521","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516727521?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 09:20","pubTimestamp":1740964800,"startTime":"0","endTime":"0","summary":"[大手成交]药明生物(02269)在上午09:20出现大手卖出，成交量为31.45万，成交价为港币$22.45，涉资706.052万。至目前为止，股价无升跌，今日最高价为$22.45，而最低价为$22.45，总成交量为198.385万股，总成交金额港币$4.449千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT25030358/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1794554557.SGD","LU0043850808.USD","LU0348825331.USD","LU1880383366.USD","LU1242518857.USD","LU0051755006.USD","BK1589","LU0516423091.SGD","LU0140636845.USD","LU0572944931.SGD","LU0417516902.SGD","LU0708995583.HKD","LU0516422952.EUR","LU0359201612.USD","LU1242518931.SGD","LU1720050803.USD","LU0039217434.USD","LU0417516738.SGD","LU0823426308.USD","BK1141","SG9999002463.SGD","LU0856984785.SGD","LU0327786744.USD","LU0348735423.USD","LU0326950275.SGD","LU0823426480.USD","LU0516423174.USD","LU0588546209.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0320764599.SGD","LU0052750758.USD","LU0819121731.USD","LU1688375341.USD","02269","LU2039709279.SGD","LU0359202008.SGD","SG9999002562.SGD","LU0307460666.USD","BK1610","LU0516422366.SGD","LU0456827905.SGD","LU0516422440.USD","BK1576","LU0456846285.SGD","BK1521","LU0181495838.USD"],"gpt_icon":0},{"id":"2516364590","title":"【百利天恆：BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌 III 期臨牀試驗完成首例受試者入組】金融界3月2日消息，百利天恆自主研發的創新生物藥注射用 BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌的 III 期臨牀試驗已於近日完成首例受試者入組。BL-B01D1 是全球獨家處於 III 期註冊臨牀試驗階段的可同時靶向 EGFR 和 HER3 的雙抗 ADC 藥物。截至目前，BL-B01D1 正在中國和美國進行約 30 項針對多種腫瘤類型的臨牀試驗，除本次新入組的臨牀試驗外，其在肺癌、乳腺癌、鼻咽癌、食管鱗癌等 7 項國內 III 期註冊臨牀試驗也處於受試者入組階段。藥品需完成臨牀試驗並通過審評審批方可上市銷售，且醫藥產品具有高科技、高風險等特點，容易受到不確定性因素影響。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364590","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364590?lang=zh_tw&edition=fundamental","pubTime":"2025-03-02 15:34","pubTimestamp":1740900843,"startTime":"0","endTime":"0","summary":"金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1 联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/02153448475153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","LU1815336091.USD","BK1141","BK4023","09939","III","159938","ADC","BL","LU0757428866.USD","BK1161","BK1574","BK4080","BK4134","03347","BK1583","159839","BK0239","BK1576","688506","BK4231"],"gpt_icon":0},{"id":"2516372983","title":"康希諾業績出爐，營收大增137%，股價不漲反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2516372983","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516372983?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 19:26","pubTimestamp":1740741978,"startTime":"0","endTime":"0","summary":"昨日，港股的疫苗企业康希诺生物（06185.HK）发布2024年度业绩快报，表现可圈可点。根据其A股三季报，康希","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202502_1/05a175fc-813c-4bc3-95e8-bed2a53c298e.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202502_1/05a175fc-813c-4bc3-95e8-bed2a53c298e.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67c19d5a23082975a38f607b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["LU0456827905.SGD","LU0043850808.USD","SG9999002463.SGD","BK1574","LU0181495838.USD","LU0819121731.USD","LU0516422366.SGD","BK1589","LU0326950275.SGD","BK1515","LU0516423091.SGD","LU0856984785.SGD","LU0456846285.SGD","BK1521","LU0052750758.USD","LU0307460666.USD","LU1242518931.SGD","LU1880383366.USD","LU0979878070.USD","SG9999002562.SGD","LU0140636845.USD","LU2039709279.SGD","06185","LU0572944931.SGD","LU0327786744.USD","LU0516423174.USD","BK1161","BK1576","LU0348825331.USD","LU0823426308.USD","BK1141","LU1242518857.USD","BK1583","LU0708995583.HKD","BK1191","LU0823426480.USD","01877","LU0051755006.USD","LU1794554557.SGD","LU0417516738.SGD","BK1610","LU0516422952.EUR","LU1688375341.USD","LU0588546209.SGD","LU0359201612.USD","LU0320764599.SGD","LU0348735423.USD","LU0516422440.USD","LU0359202008.SGD"],"gpt_icon":1}],"pageSize":16,"totalPage":14,"pageCount":7,"totalSize":218}]}}